Research in Experimental Medicine

, Volume 187, Issue 1, pp 55–58 | Cite as

Immunoreactive pancreatic secretory trypsin inhibitor in sera from patients with acute ulcerative colitis

Original Papers

Summary

The serum levels of immunoreactive pancreatic secretory trypsin inhibitor (irPSTI) and immunoreactive cationic trypsin (irCT) were measured in 14 patients admitted for severe acute attacks of ulcerative colitis. Patients with acute colitis had significantly higher irPSTI levels in serum (35 µg/l) as compared with controls (11.5 µg/l), while the serum level of irCT was within normal limits. The normal colonic mucosa recently has been shown to contain irPSTI favoring the theory of an extrapancreatic origin of the increased serum levels of irPSTI in patients with severe active ulcerative colitis.

Key words

Colitis Ileostomy content Pancreatic secretory trypsin inhibitor Trypsin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bohe M, Borgström A, Linström C, Ohlsson K (1986) Pancreatic endoproteases and pancreatic secretory trypsin inhibitor immunoreactivity in human Paneth cells. J Clin Pathol 39:786–793PubMedGoogle Scholar
  2. 2.
    Borgström A, Ohlsson K (1976) Radioimmunological determination and characterization of cathodal trypsin-like immunoreactivity in normal human plasma. Scand J Clin Lab Invest 36:809–814PubMedGoogle Scholar
  3. 3.
    Borgström A (1981) The fate of intravenously injected trypsinogens in dog. Scand J Gastroenterol 16:281–287PubMedGoogle Scholar
  4. 4.
    Eddeland A, Ohlsson K (1978) A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids. Hoppe-Seyler's Z Physiol Chem 359:671–675PubMedGoogle Scholar
  5. 5.
    Eddeland A, Wehlin L (1978) Secretin/cholecystokinin-stimulated secretion of trypsinogen and trypsin inhibitor in pure human pancreatic juice collected by endoscopic retrograde catheterization. Hoppe-Seyler's Z Physiol Chem 359:1653–1658PubMedGoogle Scholar
  6. 6.
    Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H (1982) Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 257:13713–13716PubMedGoogle Scholar
  7. 7.
    Huhtala M-J, Kahanpää K, Seppälä M, Halila H, Stenman U-H (1983) Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer 31:711–714PubMedGoogle Scholar
  8. 8.
    Kazal LA, Spicer DS, Brahinsky RA (1948) Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 70:3034–3040Google Scholar
  9. 9.
    Marks WH, Ohlsson K (1983) The elimination of pancreatic secretory trypsin inhibitor from the circulation. A study in man. Scand J Gastroenterol 18:955–959PubMedGoogle Scholar
  10. 10.
    Matsuda K, Ogowa M, Murata A, Kitahara T, Kosaki G (1983) Elevation of serum immunoreactive pancreatic secretory trypsin inhibitor contents in various malignant diseases. Res Commun Chem Pathol Pharmacol 40:301–305PubMedGoogle Scholar
  11. 11.
    Ohlsson K, Laurell C-B (1976) The disappearance of enzyme-inhibitor complexes from the circulation of man. Clin Sci Mol Med 51:87–92PubMedGoogle Scholar
  12. 12.
    Otsuki M, Oka T, Suehiro I, Okabayashi Y, Ohki A, Yuu H, Baba S (1984) Serum pancreatic secretory trypsin inhibitor in pancreatic disease. Clin Chim Acta 142:231–240PubMedGoogle Scholar
  13. 13.
    Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2:1041–1048Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • M. Bohe
    • 1
  1. 1.Depts. of Surgery and Surgical Pathophysiology, Malmö General HospitalUniversity of LundMalmöSweden

Personalised recommendations